<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51270">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438735</url>
  </required_header>
  <id_info>
    <org_study_id>2015-7/12</org_study_id>
    <nct_id>NCT02438735</nct_id>
  </id_info>
  <brief_title>Endometrioma Related Reduced Ovarian Reserve</brief_title>
  <acronym>ERROR</acronym>
  <official_title>The Effect Of The Presence Of Endometriomas On Ovarian Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uludag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of this study is to determine if the presence of endometriomas cause a reduction in
      ovarian reserve. Endometriosis and fertility problems experience are frequent. There seems
      to be an association between endometriosis and subfertility. This study aims to asses if the
      endometrioma it self causes diminished ovarian reserve after a certain time period, with
      determination of ovarian reserve with anti-mullerian hormone (AMH), follicle stimulating
      hormone (FSH),luteinizing hormone (LH), estradiol and antral follicle count (AFC) values.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned as a prospective cohort study including women with endometrioma
      diagnosis with ultrasonography. Patients with endometrioma who does not have surgery
      indication will be evaluated with ultrasonography ( for antral follicle counts (AFC) and
      ovarian volume) and blood samples will be taken for anti- müllerian hormone (AMH), follicle
      stimulating hormone ( FSH), luteinizing hormone ( LH ) and estradiol values between cycle
      days 3 and 5. Additional assessment will be done after 6 months after the first assessment.
      All the results will be statistically compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti- mullerian hormone (AMH)</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle stimulating hormone (FSH)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing hormone (LH)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antral follicle count(AFC)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Endometriosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Follicle stimulating hormone (FSH) Luteinizing hormone (LH) ESTRADİOL Anti-mullerian hormone
      (AMH)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with endometrioma diagnosis and who has not required surgery for treatment will
        be recruited. All patients will be at reproductive period. At first visit the patients
        will be evaluated for ovarian reserve markers. Serum samples will be collected in early
        follicular phase . Six months later patients will be assesed for the same markers and all
        markers will statistically compared.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reproductive age

          -  Endometrioma diagnosis without surgery indication

        Exclusion Criteria:

          -  Menstruel cycle irregularity

          -  Polycystic ovarian syndrome

          -  Pregnant patients

          -  Patients unable to give informed consent

          -  Using medication which could affect ovarian function during six months before
             recruitment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>gürkan uncu</last_name>
    <role>Study Director</role>
    <affiliation>Uludag University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gürkan Uncu</last_name>
    <phone>0224 2952541</phone>
    <email>guncu@gurkanuncu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Işıl kasapoğlu</last_name>
    <phone>0224 29535241</phone>
    <email>kasapogluisil@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uludag University Scholl of medicine</name>
      <address>
        <city>Bursa</city>
        <state>Turkey/bursa</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GÜRKAN UNCU</last_name>
      <phone>0224 2952541</phone>
      <email>guncu@gurkanuncu.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>May 13, 2015</lastchanged_date>
  <firstreceived_date>May 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uludag University</investigator_affiliation>
    <investigator_full_name>GÜRKAN UNCU,PROF. MD</investigator_full_name>
    <investigator_title>prof.md</investigator_title>
  </responsible_party>
  <keyword>ovarian endometriomas</keyword>
  <keyword>AMH</keyword>
  <keyword>ovarian reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
